首页|肝宁方对肝细胞癌的影响及作用机制初探

肝宁方对肝细胞癌的影响及作用机制初探

扫码查看
目的:研究肝宁方对肝细胞癌的作用并初步探讨其作用机制。方法:细胞实验:将40只SD大鼠予肝宁方灌胃7 d后提取含药血清。采用CCK8检测肝宁方含药血清浓度分别为5%、10%、20%、30%时对人肝癌细胞HepG2活力的影响。将HepG2细胞分为空白组和肝宁方组含药血清组,使用5%肝宁方含药血清干预24 h后提取蛋白进行质谱前处理,再进行DIA定量蛋白质组学分析,包括建立图谱数据库和DIA数据采集及分析,最后采用蛋白免疫印迹(WB)技术验证TAGLN蛋白表达水平。动物实验:10只BALB/c裸小鼠分为模型组和肝宁方组,予皮下注射人肝癌细胞MHCC-97H构建肝癌异种植瘤模型,造模成功后给予0。9%生理盐水或肝宁方灌胃,连续给药14 d。造模开始到给药结束,每隔1周测量皮下肿瘤体积,绘制肿瘤生长曲线,给药结束后剥离肿瘤,采用苏木精-伊红(HE)染色法检测肿瘤组织病理学情况。结果:细胞实验:肝宁方含药血清呈剂量依赖性降低HepG2细胞活力(P<0。05,P<0。01),选用5%肝宁方含药血清进行后续实验。DIA定量蛋白质组学分析结果发现36个上调蛋白,23个下调蛋白(P<0。05),GO富集分析显示细胞组分、细胞功能及生物学过程等。KEGG富集分析表明差异蛋白与补体和凝血级联反应、PPAR信号通路等关系密切。Reactome富集分析显示了包括血小板 α 颗粒含量的胞吐作用在内的20条信号通路。PPI网络分析发现TGFB1、SERPINE1、TAGLN等 38 种蛋白位于网络节点。WB结果发现肝宁方含药血清组TAGLN蛋白表达比空白组明显上调(P<0。01)。动物实验:通过肝癌裸鼠皮下肿瘤模型发现肝宁方能够抑制肿瘤生长(P<0。05),HE染色结果提示肝宁方可促进肿瘤坏死。结论:肝宁方能抑制HepG2细胞增殖及HCC肿瘤增长,促进肿瘤组织坏死,其作用机制涉及多个生物进程和信号通路,其中可能与调控TAGLN蛋白表达有关。
Preliminary study on the effect and mechanism of Ganning Decoction on hepatocellular carcinoma
Objective:To investigate the anti-hepatocellular carcinoma(HCC)effects of Ganning Decoction and its primary mechanisms.Methods:A total of 40 SD rats were given Ganning Decoction by gavage for 7 days,and serum samples were collect-ed.CCK8 assay was used to detect the effect of serum concentration of Ganning Decoction on the viability of human hepatoma cell line HepG2 at 5%,10%,20%and 30%,respectively.HepG2 cells were divided into blank group and Ganning Decoction-containing serum group.After 24 h of intervention with 5%serum containing Ganning Decoction,cellular proteins were extracted and processed for DIA quantitative proteomic analysis,including the establishment of atlas database and DIA data collec-tion and analysis.The expression of TAGLN protein was detected by Western blot(WB).10 BALB/c nude mice were divided in-to model group and Ganning Decoction group.The HCC model was established by subcutaneous injection of human liver cancer cell line MHCC-97H.After successful modeling,0.9%normal saline or Ganning Decoction was given by gavage for 14 days.The subcutaneous tumor volume was measured every one week from the beginning of modeling to the end of administration and the drew tumor growth curve.After the end of administration,the tumors were dissected,and the histopathological examination of the tumors were detected by hematoxylin-eosin(HE)staining.Results:Ganning Decoction-containing serum decreased HepG2 cell vi-ability in a dose-dependent manner(P<0.05,P<0.01).5%Ganning Decoction-containing serum was used for subsequent experi-ments.DIA quantitative proteomics analysis showed 36 up-regulated proteins and 23 down-regulated proteins(P<0.05).GO en-richment analysis showed cellular component,molecular function and biological process.KEGG enrichment analysis outcomes pointed out the discrepant proteins were closely related to complement and coagulation cascades,PPAR signaling pathway,etc.Reactome enrichment analysis revealed 20 signaling pathways including exocytosis of platelet alpha granule contents.PPI network showed that 38 proteins such as TGFB1,SERPINE1 and TAGLN were in the network nodes.WB validation results show that the expression of TAGLN in Ganning Decoction group was significantly higher than that in the blank group(P<0.01).The subcu-taneous model of HCC in nude mice showed that Ganning Decoction could inhibit tumors growth(P<0.05),and HE staining showed that Ganning Decoction could promote tumor necrosis.Conclusion:Ganning Decoction can inhibit the proliferation of HepG2 cells and tumors,and promote the tumor necrosis.The mechanism involves multiple biological processes and signaling pathways,which may be related to the regulation of TAGLN protein expression.

Ganning decoctionHepatocellular carcinomaProteomicsTAGLN protein expression

彭佩纯、邓鑫、陈然、陈泽山、陈少锋

展开 >

广西中医药大学,壮医临床医学院,广西 南宁 530201

广西中医药大学,基础医学院,广西 南宁 530201

福建医科大学附属厦门弘爱医院,消化内科,福建 厦门 361000

广西壮族自治区人民医院,中医科,广西 南宁 530000

展开 >

肝宁方 肝癌 蛋白质组学 TAGLN蛋白表达

广西自然科学基金广西中医药大学"桂派中医药传承创新团队"广西中医药大学全国名老中医黄汉儒学术思想与临床诊疗传承发展推广中心

2021GXNSFBA2200372022B0042022V004

2024

海南医学院学报
海南医学院

海南医学院学报

CSTPCD北大核心
影响因子:1.068
ISSN:1007-1237
年,卷(期):2024.30(20)